From: BRCA1/2 genetic background-based therapeutic tailoring of human ovarian cancer: hope or reality?
Parp-inhibitors | Pharmaceutical Company | Clinical development |
---|---|---|
Olaparib (AZD2281) | AstraZeneca | Breast, ovarian and prostate cancer BRCA1-BRCA2 related Breast cancer Ovarian cancer Pacreatic cancer Colorectal cancer Melanoma neoplasm Unspecified adult solid tumors |
BSI-201 | BiPar Sciences Inc. | Uterine cancer Brain neoplasm Triple negative breast cancer |
ABT-888 | Abbott | Metastatic Melanoma Skin cancer Breast Cancer Ovarian Cancer Primary Peritoneal Cancer Fallopian Tube Cancer |
MK 4827 | Merck & Co. Inc. | BRCA-related ovarian cancer Ovarian cancer Solid tumors |